BDT方案治疗多发性骨髓瘤的临床疗效  

Effect of BDT regimen in the treatment of multiple myeloma

作　　者：林火真[1] 代宏勋[1] 

机构地区：[1]成都市第五人民医院血液科,四川成都611130

出　　处：《现代肿瘤医学》2016年第16期2603-2606,共4页Journal of Modern Oncology

摘　　要：目的：探讨应用BDT（硼替佐米＋地塞米松＋沙利度胺）方案治疗多发性骨髓瘤（MM）临床疗效及安全性。方法：硼替佐米每周注射2次,每次注射1.3mg/m2,连续2周（即第1、4、8、11天）,地塞米松20mg,第1~4d静脉滴注,28d为1个疗程。同时早晚口服沙利度胺100mg,连续服用28d（1个疗程）。结果：31例MM患者,经过3个疗程联合化疗,完全缓解（CR）8例,非常好的部分缓解（VGPR）13例,部分缓解（PR）5例,疾病稳定（SD）3例,总有效率（OR）83.87%,其中,初治组21例患者有效率85.71%,复发或难治组10例患者有效率80.00%,两组疗效比较差异无统计学意义（P〉0.05）,与治疗前比较,治疗后M-蛋白、β2-微球蛋白及骨髓浆细胞数均有明显下降,而血红蛋白（HGB）有显著上升,治疗前后各项观察指标的变化差异具有显著性,有统计学意义（P〈0.05）。结论：BDT联合化疗方案治疗多发性骨髓瘤（MM）完全缓解（CR）率高,起效快,毒副反应小,耐受性好,对于初治、复发或难治MM患者均可获得较为满意的临床疗效,值得临床推广应用。Objective：To study the clinical efficacy and safety of BDT（Bortezomib ＋ Dexamethasone ＋ Thalido-mide）regimen in the treatment of multiple myeloma（MM）. Methods：Bortezomib injection was used 2 times per week,each injection of 1. 3mg/ m2 ,2 consecutive weeks（1,4,8,11 days）,Dexamethasone 20mg,the first 1 ~ 4d in-travenous drip,28d for 1 courses. Results：Of 31 patients MM,after 3 courses treatment,complete remission（CR）in 8 cases,very good partial remission（VGPR）in 13 cases,partial remission（PR）5 cases,stable disease（SD）in 3 ca-ses,the total efficiency 83. 87% . Among them,the initial treatment group 21 patients,the effective rate was 85. 71% , relapsed or refractory group 10 patients,the effective rate was 80. 00%（P ﹥ 0. 05）. Hemoglobin（HGB）was signifi-cantly increased,the observed indexes before and after treatment were significantly different（P ﹤ 0. 05）. Conclusion：BDT combined with chemotherapy regimen in the treatment of multiple myeloma（MM）complete remission（CR）rate was higher,with less adverse reaction,good tolerance. For the initial treatment,relapsed or refractory MM patients can obtain satisfactory clinical effect.

关 键 词：多发性骨髓瘤(MM) BDT方案 不良反应 疗效 

分 类 号：R733.3[医药卫生—肿瘤]